Medtronic Signs Exclusive Distribution Agreement to Commercialize Kuros Biosciences’ MagnetOs Bone Graft Technology in the U.S.

Jan 11, 2025 10:16 CST Updated 10:16

Medtronic

Medical Device Manufacturer

Kuros Biosciences

Biopharmaceutical Manufacturer

Source: Bone Future; Editor: Jane

Reprint Requirements: You can directly repost, please credit the source at the beginning of the article.

January 10, 2025,MedtronicKuros Biosciences' U.S. Subsidiary Announces Exclusive Five-Year Sales Agency Agreement to DriveKuros BiosciencesPromotion of MagnetOs Bone Graft Technology in the U.S. Market.

# Overview of Cooperation

Kuros Biosciences USA (headquartered in Atlanta, USA) is a wholly-owned subsidiary of Kuros Biosciences AG (headquartered in Zurich, Switzerland). The two parties had previously reached a pilot cooperation agreement. This upgraded agreement grants Medtronic exclusive sales rights for the MagnetOs bone graft product in part of the U.S. spinal market.

The core technology of the MagnetOs bone graft product isNeedleGrip Surface Technology, by attracting human "pro-healing" immune cells (M2 macrophages), stimulates stem cells to generate new bone. The main features of this technology include:

Immunomodulation: By modulating the activity of M2 macrophages, it promotes bone regeneration and increases the success rate of bone fusion;
Enhanced Bone FusionCompared with traditional bone graft products, MagnetOs can provide more predictable bone fusion results and reduce the risk of postoperative failure.
Diversified Product FormatsThe products include MagnetOs Putty (paste-like bone graft material) and MagnetOs Granules (granular bone graft material), suitable for different surgical needs.

It should be noted that MagnetOs has not yet been certified as an osteoinductive material by the U.S. Food and Drug Administration (FDA) or the Australian Therapeutic Goods Administration (TGA), but its clinical application potential has received widespread attention.

# Business Value and Cooperation Prospects

According to data released by Kuros Biosciences, sales of the MagnetOs product reached 50.6 million Swiss francs (approximately 57.4 million US dollars) in the first three quarters of 2024, a year-on-year increase of 149%. This collaboration with Medtronic will further enhance the market penetration of MagnetOs and help drive its market expansion.

Kuros Biosciences CEO Chris Fair stated, "This transition from a pilot collaboration to a strategic alliance marks a significant development milestone for Kuros. This partnership will help us accelerate production scale-up, optimize operational efficiency, and achieve continuous revenue growth through collaboration with Medtronic and direct sales channels."

# MagnetOs Product Introduction

MagnetOsIt is an innovative bone graft material developed by Kuros Biosciences, a Swiss company, and has become one of the leading solutions in the field of bone transplantation due to its unique mechanism of action and excellent clinical performance. The following is a rigorous introduction to its main features and advantages:

1. Working Mechanism: Based on Osteoimmunology

MagnetOs promotes new bone formation through a series of immunomodulatory processes, and its working mechanism includes the following three key steps:

Polarization：
The submicron needle-like surface features of MagnetOs are able to polarize immune cells into pro-healing M2 macrophages.
Regeneration：
Polarized M2 macrophages release regenerative signaling factors, attracting stem cells to migrate to the transplantation area and promoting their proliferation and differentiation into osteoblasts.
Propagation：
This process continues throughout the entire graft material, progressively guiding new bone formation and achieving stable bone regeneration effects.

2. Clinical manifestations: Research data support

MagnetOs Demonstrates Excellent Bone Regeneration Capabilities in Multiple Clinical Studies:

MAXA Study：
In a prospective, multicenter, randomized Level 1 study, MagnetOs demonstrated high efficacy as an autograft replacement in challenging posterolateral fusion procedures.

Effect ComparisonStudies show that MagnetOs may perform better in the posterolateral fusion area than the current gold standard — autologous bone grafting.

Clinical Application Scenarios: Particularly suitable for complex bone fusion surgeries or patients with poor bone quality, it is a safe and predictable bone grafting solution.

3. Product Variants: Meeting Diverse Surgical Needs

Kuros Biosciences offers a variety of MagnetOs products to accommodate different surgical scenarios:

MagnetOs Flex Matrix：

It is an open fibrous matrix that combines flexibility and ease of handling, allowing surgeons to tear, shape, or fold it as needed for precise filling of bone voids.
Particularly suitable for complex bone structures and irregular bone defect areas.

4. Scientific Support: Technological Breakthroughs in Immunology and Surface Engineering

The technical basis of MagnetOs is supported by multiple studies:

A translational study published in the journal "European Cells and Materials" conducted an in-depth analysis ofThe Modulatory Effect of Submicron Topography on Immune Responses, demonstrating that modulating the innate immune response can effectively enhance biomaterial-guided bone formation.
Studies have confirmed that through surface topology optimization, MagnetOs can effectively induce pro-healing responses in immune cells, providing more stable and efficient support for bone regeneration.

# Introduction to Kuros Biosciences

Kuros Biosciences is a Switzerland-based biotechnology company dedicated to developing innovative bone healing technologies. The companyFounded in 2000, it is a spin-off from the Swiss Federal Institute of Technology ZurichCompany;Listed on the Swiss Stock Exchange in 2016;With operations in the United States, Switzerland, and the Netherlands;With 150 years of experience in spinal biologics research.

Orthopedic Communication Community(Copy the following link to fill in)

https://docs.qq.com/form/page/DUGtnQmpKcHJ4TXdO

Innovative Orthopedic Medical Devices

China Orthopedic Innovation Device List [2023 Year in Review]

International Orthopedic Enterprises

Stryker｜Johnson & Johnson|Zimmer Biomet ｜Medtronic | Smith+Nephew｜Enovis ｜NuVasive | Globus Medical｜Orthofix｜CONMED

Chinese Orthopedic Enterprises

Chunli Medical｜Sanyou Medical ｜WEGO Orthopaedics ｜Dabo Medical | Kailite Medical｜Aurora Medical ｜Haohai BioScience ｜AK Medical